FDA Update: Sotagliflozin Approved For Broad HF Treatment
WEBJun 5, 2023 · The U.S. Food and Drug Administration (FDA) on May 26 approved a new drug application submitted by Lexicon Pharmaceuticals, Inc. for sotagliflozin (Inpefa), the first dual SGLT1 and SGLT2 inhibitor for the treatment of heart failure (HF), including HF with preserved ejection fraction and HF with reduced ejection fraction.
Some Diabetes Meds Could Lower Odds for Dementia, Parkinson's
WEB1 day ago · US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. ... Alzheimer’s disease among people on SGLT2 inhibitors was just under 40 cases per 10,000 ...
SGLT2 inhibitor empagliflozin is shown to be safe and effective for ...
WEBSep 2, 2024 · The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction...
Some diabetes drugs tied to lower risk of dementia, Parkinson's …
WEB1 day ago · For vascular dementia, which is dementia caused by vascular disease, the incidence rate for people taking the SGLT2 drugs was 10.6 cases per 10,000, compared to 18.7 for those taking the other drugs.
GLP-1 Receptor Agonists vs SGLT2 Inhibitors and Kidney, Heart …
WEB17 hours ago · Similar kidney and cardiovascular outcomes are found with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) vs sodium-glucose cotransporter 2 inhibitors (SGLT2i) in people with type 2 diabetes (T2D), according to study findings published in the Journal of the American College of Cardiology.. New users of GLP-1 RAs and SGLT2is were compared for kidney and cardiovascular outcomes.
FDA approves first SGLT1/SGLT2 inhibitor for heart failure
WEBJun 29, 2023 · Patients now have an even better chance at survival with the recent FDA approval of Inpefa, the brand name of the drug sotagliflozin. It is the first sodium glucose cotransporter (SGLT) inhibitor that addresses glucose reabsorption in both the kidneys and the small intestine.
SGLT2 Inhibitors Reduce Cardiovascular Risks Independent of GLP …
WEBJun 20, 2024 · Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular and kidney outcomes in patients with type 2 diabetes with or without concomitant use of glucagon-like peptide-1...
Applications of SGLT2 inhibitors beyond glycaemic control
WEBApr 26, 2024 · Sodium–glucose cotransporter 2 (SGLT2) inhibitors were initially developed for their glucose-lowering effects and have shown a modest glycaemic benefit in people with type 2 diabetes...
SGLT2 Inhibitors Cut Kidney Risks Across CKD, Heart Failure, …
WEB2 days ago · SGLT2 inhibitors reduce the risk for adverse kidney outcomes across most high-risk populations with CKD, heart failure, and/or type 2 diabetes. Sodium glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk for adverse kidney outcomes across patient groups with different combinations of chronic kidney disease (CKD), type 2 …
SGLT inhibitors: a serendipitous glycaemic tale - Nature
WEBNov 20, 2023 · SGLT2 present in the early proximal convoluted tubule of nephrons reabsorbs the majority of glucose from the glomerular filtrate, whereas SGLT1 reabsorbs the remaining glucose in the late...